Calidi Biotherapeutics (CLDI) Competitors $1.58 -0.07 (-4.24%) Closing price 09/3/2025 04:00 PM EasternExtended Trading$1.64 +0.06 (+3.80%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. FNCH, ABP, AIMD, ATNF, LEXX, MTEX, EDSA, SYBX, LSB, and LPCNShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Finch Therapeutics Group (FNCH), Abpro (ABP), Ainos (AIMD), 180 Life Sciences (ATNF), Lexaria Bioscience (LEXX), Mannatech (MTEX), Edesa Biotech (EDSA), Synlogic (SYBX), LakeShore Biopharma (LSB), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors Finch Therapeutics Group Abpro Ainos 180 Life Sciences Lexaria Bioscience Mannatech Edesa Biotech Synlogic LakeShore Biopharma Lipocine Calidi Biotherapeutics (NYSE:CLDI) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations. Do insiders & institutionals have more ownership in CLDI or FNCH? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 6.7% of Calidi Biotherapeutics shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media prefer CLDI or FNCH? In the previous week, Calidi Biotherapeutics and Calidi Biotherapeutics both had 1 articles in the media. Calidi Biotherapeutics' average media sentiment score of 0.00 beat Finch Therapeutics Group's score of -1.00 indicating that Calidi Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Calidi Biotherapeutics Neutral Finch Therapeutics Group Negative Is CLDI or FNCH more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Finch Therapeutics Group's return on equity.Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Finch Therapeutics Group N/A -69.14%-26.92% Which has more risk and volatility, CLDI or FNCH? Calidi Biotherapeutics has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. Which has stronger earnings & valuation, CLDI or FNCH? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi BiotherapeuticsN/AN/A-$29.22MN/AN/AFinch Therapeutics GroupN/AN/A-$74.75M-$8.82-1.43 SummaryFinch Therapeutics Group beats Calidi Biotherapeutics on 4 of the 7 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$5.65M$282.79M$5.77B$21.33BDividend YieldN/AN/A6.66%3.49%P/E RatioN/AN/A82.3829.14Price / SalesN/A537.82498.4347.14Price / CashN/A22.4425.7018.29Price / Book-0.6811.8111.055.30Net Income-$29.22M-$115.81M$3.28B$998.51M7 Day Performance-7.60%2.01%0.12%-0.63%1 Month Performance-77.80%0.71%8.96%4.90%1 Year Performance-88.55%-13.13%53.91%13.95% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics0.702 of 5 stars$1.58-4.2%N/A-88.2%$5.65MN/A0.0038Gap DownFNCHFinch Therapeutics Group0.4963 of 5 stars$12.25-3.6%N/A-3.9%$19.67MN/A-1.39190Negative NewsShort Interest ↑Gap DownABPAbproN/A$0.25+1.1%$4.00+1,532.7%N/A$19.43M$180K0.0015AIMDAinos0.1496 of 5 stars$3.80-7.5%N/A+20.8%$19.14M$20K0.0040Negative NewsShort Interest ↑ATNF180 Life Sciences0.3226 of 5 stars$3.10+0.8%N/A+50.8%$18.72MN/A-0.217Gap DownLEXXLexaria Bioscience2.9796 of 5 stars$0.89-4.7%$4.00+351.6%-75.7%$18.17M$460K-1.327Short Interest ↑MTEXMannatech0.4317 of 5 stars$8.85-3.6%N/A+18.3%$17.45M$117.87M-4.34250News CoverageShort Interest ↑EDSAEdesa Biotech1.23 of 5 stars$2.40-1.2%$5.00+108.3%-43.0%$17.10MN/A-1.8220SYBXSynlogicN/A$1.46flatN/A+4.2%$17.08M$10K-18.2580LSBLakeShore Biopharma1.3591 of 5 stars$0.80-2.2%N/A-81.2%$16.88M$85.67M0.00773Short Interest ↓LPCNLipocine2.9978 of 5 stars$3.01-2.9%$9.00+199.0%-20.5%$16.80M$11.20M-3.4610 Related Companies and Tools Related Companies Finch Therapeutics Group Competitors Abpro Competitors Ainos Competitors 180 Life Sciences Competitors Lexaria Bioscience Competitors Mannatech Competitors Edesa Biotech Competitors Synlogic Competitors LakeShore Biopharma Competitors Lipocine Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThis Massive Market is Ripe for Disruption by this NasdaqFanatics Hit $31B. This Nasdaq Company Is Building the Next Wave Fanatics built a merch empire by owning th...i2i Marketing Group, LLC | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Shadow Group” in Washington, DC Could Crash MarketNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much b...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
